Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 6.43
NONOF's Cash to Debt is ranked higher than
68% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. NONOF: 6.43 )
NONOF' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 6.43

Equity to Asset 0.53
NONOF's Equity to Asset is ranked higher than
63% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NONOF: 0.53 )
NONOF' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.73
Current: 0.53

0.51
0.73
Interest Coverage 572.60
NONOF's Interest Coverage is ranked higher than
59% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NONOF: 572.60 )
NONOF' s 10-Year Interest Coverage Range
Min: 5.69   Max: 572.6
Current: 572.6

5.69
572.6
F-Score: 7
Z-Score: 18.03
M-Score: -1.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 37.68
NONOF's Operating margin (%) is ranked higher than
97% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. NONOF: 37.68 )
NONOF' s 10-Year Operating margin (%) Range
Min: 10.5   Max: 37.77
Current: 37.68

10.5
37.77
Net-margin (%) 30.13
NONOF's Net-margin (%) is ranked higher than
96% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. NONOF: 30.13 )
NONOF' s 10-Year Net-margin (%) Range
Min: 11.39   Max: 30.13
Current: 30.13

11.39
30.13
ROE (%) 59.16
NONOF's ROE (%) is ranked higher than
99% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. NONOF: 59.16 )
NONOF' s 10-Year ROE (%) Range
Min: 10.84   Max: 59.16
Current: 59.16

10.84
59.16
ROA (%) 35.80
NONOF's ROA (%) is ranked higher than
98% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. NONOF: 35.80 )
NONOF' s 10-Year ROA (%) Range
Min: 7.75   Max: 35.8
Current: 35.8

7.75
35.8
ROC (Joel Greenblatt) (%) 124.83
NONOF's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. NONOF: 124.83 )
NONOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.65   Max: 124.83
Current: 124.83

6.65
124.83
Revenue Growth (%) 14.30
NONOF's Revenue Growth (%) is ranked higher than
87% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. NONOF: 14.30 )
NONOF' s 10-Year Revenue Growth (%) Range
Min: -46.2   Max: 186.8
Current: 14.3

-46.2
186.8
EBITDA Growth (%) 19.00
NONOF's EBITDA Growth (%) is ranked higher than
92% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NONOF: 19.00 )
NONOF' s 10-Year EBITDA Growth (%) Range
Min: -44.6   Max: 190.7
Current: 19

-44.6
190.7
EPS Growth (%) 23.90
NONOF's EPS Growth (%) is ranked higher than
93% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. NONOF: 23.90 )
NONOF' s 10-Year EPS Growth (%) Range
Min: -4.5   Max: 72.8
Current: 23.9

-4.5
72.8
» NONOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NONOF



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.80
NONOF's P/E(ttm) is ranked higher than
93% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 26.80 )
NONOF' s 10-Year P/E(ttm) Range
Min: 8.17   Max: 28.32
Current: 26.8

8.17
28.32
P/B 20.90
NONOF's P/B is ranked higher than
56% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. NONOF: 20.90 )
NONOF' s 10-Year P/B Range
Min: 1.57   Max: 20.9
Current: 20.9

1.57
20.9
P/S 8.30
NONOF's P/S is ranked higher than
81% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. NONOF: 8.30 )
NONOF' s 10-Year P/S Range
Min: 2.21   Max: 9.14
Current: 8.3

2.21
9.14
PFCF 35.40
NONOF's PFCF is ranked higher than
93% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 35.40 )
NONOF' s 10-Year PFCF Range
Min: 8.45   Max: 56.49
Current: 35.4

8.45
56.49
EV-to-EBIT 21.71
NONOF's EV-to-EBIT is ranked higher than
93% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 21.71 )
NONOF' s 10-Year EV-to-EBIT Range
Min: 6   Max: 27
Current: 21.71

6
27
PEG 1.20
NONOF's PEG is ranked higher than
98% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 1.20 )
NONOF' s 10-Year PEG Range
Min: 0.05   Max: 5.34
Current: 1.2

0.05
5.34
Shiller P/E 39.60
NONOF's Shiller P/E is ranked higher than
96% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 39.60 )
NONOF' s 10-Year Shiller P/E Range
Min: 10.52   Max: 43.15
Current: 39.6

10.52
43.15
Current Ratio 1.31
NONOF's Current Ratio is ranked higher than
53% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. NONOF: 1.31 )
NONOF' s 10-Year Current Ratio Range
Min: 1.31   Max: 2.88
Current: 1.31

1.31
2.88
Quick Ratio 0.92
NONOF's Quick Ratio is ranked higher than
53% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. NONOF: 0.92 )
NONOF' s 10-Year Quick Ratio Range
Min: 0.92   Max: 2.34
Current: 0.92

0.92
2.34

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.80
NONOF's Dividend Yield is ranked higher than
78% of the 166 Companies
in the Global Biotechnology industry.

( Industry Median: 1.11 vs. NONOF: 1.80 )
NONOF' s 10-Year Dividend Yield Range
Min: 1.02   Max: 2.47
Current: 1.8

1.02
2.47
Dividend Payout 0.47
NONOF's Dividend Payout is ranked higher than
94% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 0.47 )
NONOF' s 10-Year Dividend Payout Range
Min: 0.51   Max: 1.61
Current: 0.47

0.51
1.61
Dividend growth (3y) 33.90
NONOF's Dividend growth (3y) is ranked higher than
93% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. NONOF: 33.90 )
NONOF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 37.5
Current: 33.9

0
37.5
Yield on cost (5-Year) 5.32
NONOF's Yield on cost (5-Year) is ranked higher than
96% of the 170 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. NONOF: 5.32 )
NONOF' s 10-Year Yield on cost (5-Year) Range
Min: 3.01   Max: 7.3
Current: 5.32

3.01
7.3
Share Buyback Rate 2.70
NONOF's Share Buyback Rate is ranked higher than
98% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. NONOF: 2.70 )
NONOF' s 10-Year Share Buyback Rate Range
Min: 59.6   Max: -92.3
Current: 2.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 21.80
NONOF's Price/Tangible Book is ranked higher than
61% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. NONOF: 21.80 )
NONOF' s 10-Year Price/Tangible Book Range
Min: 1.58   Max: 21.28
Current: 21.8

1.58
21.28
Price/DCF (Projected) 3.70
NONOF's Price/DCF (Projected) is ranked higher than
93% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 3.70 )
NONOF' s 10-Year Price/DCF (Projected) Range
Min: 0.91   Max: 23.73
Current: 3.7

0.91
23.73
Price/Median PS Value 2.00
NONOF's Price/Median PS Value is ranked higher than
70% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NONOF: 2.00 )
NONOF' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 1.9
Current: 2

0.18
1.9
Price/Peter Lynch Fair Value 1.20
NONOF's Price/Peter Lynch Fair Value is ranked higher than
99% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 1.20 )
NONOF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.07   Max: 3.64
Current: 1.2

0.07
3.64
Price/Graham Number 5.20
NONOF's Price/Graham Number is ranked higher than
88% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NONOF: 5.20 )
NONOF' s 10-Year Price/Graham Number Range
Min: 0.79   Max: 5
Current: 5.2

0.79
5
Earnings Yield (Greenblatt) 4.60
NONOF's Earnings Yield (Greenblatt) is ranked higher than
68% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. NONOF: 4.60 )
NONOF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.7   Max: 16.6
Current: 4.6

3.7
16.6
Forward Rate of Return (Yacktman) 24.16
NONOF's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. NONOF: 24.16 )
NONOF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.9   Max: 176.8
Current: 24.16

3.9
176.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:NVO.USA, 0QIU.country, NOVO B.Denmark, NOVA.Germany, NOVC.Germany
Novo Nordisk is a healthcare company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The company operates in two business segments, diabetes care and biopharmaceuticals. The diabetes care segment covers insulin's, GLP-1, other protein-related products and projects such as glucagon and protein-related delivery systems, obesity and oral anti-diabetic drugs. The biopharmaceuticals segment covers the therapy areas of hemophilia, growth hormone therapy, hormone replacement therapy and inflammation. The company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
» More Articles for OTCPK:NONOF

Headlines

Articles On GuruFocus.com
GAMCO CIO Howard Ward on Reliable Consumer Stock Ideas Apr 09 2014 
Assessing the New Boss at National Oilwell Varco Mar 31 2014 
Amgen Inc: As Good as It Gets? Feb 20 2014 
Shire PLC: Time to Panic? Feb 07 2014 
Weekly 52-Week Highs Highlight: ACT, NVO, NXPI, WYNN Feb 03 2014 
AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is Jan 15 2014 
Sanofi Continues to Struggle on Its Path to Recovery Nov 23 2013 
Renaissance Man Jim Simons - A Tale of Three Pharmaceuticals and Remarkable Gains Jul 21 2013 
Comment for Jan 27 2013 
The 3 Most-Recommended Healthcare Stocks Jan 02 2013 

More From Other Websites
Gains in healthcare stocks prop up European equities Jun 17 2014
Gains in healthcare stocks prop up European equities Jun 17 2014
Chinese city targets pharma firms in graft crackdown May 27 2014
Novo Nordisk earnings rise, lowers sales forecast May 01 2014
[video] 'Focus' key amid healthcare M&A: Novo Nordisk CFO May 01 2014
FDA approves GSK's Tanzeum to treat type 2 diabetes Apr 15 2014
FDA approves GSK's Tanzeum to treat type 2 diabetes Apr 15 2014
Is Biogen A Value Stock Yet? Apr 15 2014
Status regarding Novo Nordisk's holding of its own shares (31 March 2014) Apr 01 2014
Weight loss surgery helps many reverse type 2 diabetes - study Mar 31 2014
Weight loss surgery helps reverse type 2 diabetes for some -study Mar 31 2014
Trading in Novo Nordisk shares by board members, executives and associated persons on 24 March 2014 Mar 25 2014
Share repurchase programme Mar 24 2014
Russian sanctions ripple through corporate boardrooms Mar 21 2014
2014 long-term, share based incentive programme for Novo Nordisk's Senior Management Board Mar 21 2014
Resolutions from the Annual General Meeting of Novo Nordisk A/S Mar 20 2014
Positive results from first phase 3 trial with N8-GP, a long-acting factor VIII for treatment of... Mar 19 2014
Share repurchase programme Mar 17 2014
Five European funds for your 2014 Isa Mar 14 2014
Europe open: Stocks fall as US and Russia hold talks on Ukraine Mar 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Gintaras58
ReplyGintaras58 - 4 months ago
few excellent prducts to come soon

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide